Plasma tau biomarkers for biological staging of Alzheimer’s disease
Laia Montoliu‐Gaya(University of Gothenburg), Oskar Hansson(Lund University), Gunnar Brinkmalm(University of Gothenburg), Sebastian Palmqvist(Lund University), Erik Stomrud(Lund University), Kaj Blennow(Sahlgrenska University Hospital), Juan Lantero‐Rodriguez(University of Gothenburg), Sophia Weiner(Institute of Neurobiology), Niklas Mattsson(Lund University), Nesrine Rahmouni(McGill University), Andréa Lessa Benedet(McGill University), Gemma Salvadó(Lund University), Johanna Nilsson(University of Gothenburg), Henrik Zetterberg(Queen Mary University of London), Shorena Janelidze(Lund University), Pedro Rosa‐Neto(Montreal Neurological Institute and Hospital), Johan Gobom(Sahlgrenska University Hospital), Nicholas J. Ashton(King's College London), Joseph Therriault(Douglas Mental Health University Institute)
Cited by 17
Related Papers
Mild cognitive impairment – beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment
|Journal of Internal Medicine|2004|5k
Defeating Alzheimer's disease and other dementias: a priority for European science and society
|The Lancet Neurology|2016|1.7k
Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts
|The Lancet Neurology|2020|1.3k
Earliest accumulation of β-amyloid occurs within the default-mode network and concurrently affects brain connectivity
|Nature Communications|2017|927